Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
Author:
Publisher
Elsevier BV
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference30 articles.
1. PCSK9 inhibitors: a new era of lipid lowering therapy;Chaudhary;World J Cardiol,2017
2. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia;Paton;Drugs Today (Barc),2016
3. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab;Blom;Vasc Health Risk Manag,2016
4. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors;Khan;Circ Cardiovasc Qual Outcomes,2017
5. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events;Robinson;N Engl J Med,2015
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a);Pharmaceuticals;2023-04-12
2. Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat;Frontiers in Cardiovascular Medicine;2022-12-02
3. Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis;Metabolism;2022-11
4. Progress and prospects of therapeutic vaccines for cardiovascular diseases;SCIENTIA SINICA Vitae;2022-01-29
5. Advances in biological therapies for dyslipidemias and atherosclerosis;Metabolism;2021-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3